METHODS: Decision analysis was conducted using population-based vaccination coverage, published vaccine efficacies, historical data on disease incidence before vaccination, and disease incidence reported during 2005 to 2009. Costs were estimated using the direct cost and societal (direct and indirect costs) perspectives. Program costs included vaccine, administration, vaccine-associated adverse events, and parent travel and work time lost. All costs were inflated to 2009 dollars, and all costs and benefits in the future were discounted at a 3% annual rate. A hypothetical 2009 US birth cohort of 4 261 494 infants over their lifetime was followed up from birth through death. Net present value (net savings) and benefit-cost ratios of routine childhood immunization were calculated.
RESULTS:
Analyses showed that routine childhood immunization among members of the 2009 US birth cohort will prevent ∼42 000 early deaths and 20 million cases of disease, with net savings of $13.5 billion in direct costs and $68.8 billion in total societal costs, respectively. The direct and societal benefit-cost ratios for routine childhood vaccination with these 9 vaccines were 3.0 and 10.1.
CONCLUSIONS:
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In the United States the widespread use of vaccines, frequently cited as among the most effective preventive health care measures, has resulted in dramatic decreases in the incidence of vaccinepreventable diseases and corresponding declines in morbidity and mortality. Remarkable success has been observed not only for vaccines in use for decades, but also for more recently introduced vaccines, including pneumococcal conjugate and rotavirus vaccines. [1] [2] [3] [4] [5] [6] In addition to the health benefits that have accrued from the US immunization program, cost savings have accrued as well. The first evaluation of the economic impact of all vaccines in the routine US childhood immunization schedule assessed the 2001 schedule (excluding the newly added pneumococcal conjugate and influenza vaccines); this evaluation documented substantial cost savings over the lifetimes of the cohort of children born in 2001. 7 The study used consistent methods and assumptions for each vaccine assessed and thus provided comprehensive economic information of uniform consistency for making US vaccine policy and immunization program decisions.
Since the analysis of routinely used vaccines in the 2001 schedule, pneumococcal conjugate vaccine has become widely used, and hepatitis A and rotavirus vaccines were added to the schedule, along with a second dose of varicella vaccine. 8 In addition, costs for vaccination have risen, in part because more vaccines are recommended and because in general newer vaccines are more expensive than older ones. Of note, costs for treatment of vaccine-preventable diseases that do occur have also risen. This report updates our previous evaluation, using the same methods to estimate the costs and benefits of vaccinating the cohort of children born in 2009, following members from birth to death. We include vaccines routinely recommended for children in 2009: diphtheria and tetanus toxoids and acellular pertussis (DTaP), Haemophilus influenzae type b conjugate (Hib), inactivated poliovirus (IPV), measles/ mumps/rubella (MMR), hepatitis B (HepB), varicella (VAR), 7-valent pneumococcal conjugate (PCV7), hepatitis A (HepA), and rotavirus (Rota) vaccines. Although recommended for routine immunization, influenza vaccine is not included in this analysis because it is administered annually and methods for assessing costs and impact differ substantially than those for other vaccines.
METHODS

Decision Analysis Model
We developed 1 decision tree for each vaccine as the basis for our model (see for example, Fig 1) 12 The analyses were performed from 2 perspectives: direct cost (direct medical and nonmedical costs) and societal (direct and indirect costs). Direct medical costs include those associated with treating an initial infection as well as costs associated with complications and sequelae of diseases. Direct nonmedical costs include travel costs, costs for special education of children disabled by diseases, and costs for other supplies for special needs. Indirect costs include the productivity losses owing to premature mortality and permanent disability among cohort members, as well as opportunity costs associated with parents who miss work to care for their sick children or cohort members themselves who miss work owing to vaccine-preventable illness. Benefits of routine childhood immunization are quantified as the savings in direct and indirect costs that accrue from averting morbidity and mortality by vaccination. The costs associated with the immunization program include the vaccines, their administration, parent travel, and work time lost and adverse events associated with these vaccines. All costs were adjusted to 2009 dollars by using general and
FIGURE 1
Simplified decision tree.
medical Consumer Price Indices, and all costs and benefits in the future were discounted at a 3% annual rate. We calculated net present values (NPV) and benefit-cost ratios (BCRs) for all vaccines together. NPV is the sum of the discounted benefits from the routine childhood immunization program minus the sum of the discounted costs, and BCR is equal to the discounted benefits divided by the discounted immunization program costs. The incremental benefit-cost ratios for PCV7, HepA, and Rota vaccines were also calculated.
The data for burden of diseases, costs of diseases, costs for outbreak control, and costs of vaccination and adverse events used in our analysis were compiled from a variety of sources: the published literature, including surveillance data, study data, and expert consensus; several large computerized data sets; and CDC unpublished data. When it was necessary to make estimates about the incidence of disease and complications from multiple publications, results from existing metaanalyses were used.
Estimating the Burden of Diseases Without Vaccination
Theage-specificannualincidenceratesof diphtheria, tetanus, pertussis, Hib, poliomyelitis, measles, mumps, rubella, and varicella diseases, and the prevalence, complications, and perinatal transmission of hepatitis B in the United States in the pre-vaccine era were obtained from the previous analysis (Table 1) . 7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] For pneumococcus-related diseases, the age-specific estimated incidence rates in the United States in the prevaccine era were obtained from the CDC' s Active Bacterial Core Surveillance (ABCs) program (for invasive pneumococcal diseases, or IPD) and the literature (for pneumonia and acute otitis media). [28] [29] [30] [31] Age-specific pre-vaccine IPD rates and case-fatality rates for IPD were based on data from the ABCs program for 1998 and 1999. All-cause pneumonia incidence and acute otitis media rates were obtained from the literature. [28] [29] [30] [31] For hepatitis Avirus infection, pre-vaccine age-and region-specific incidence estimates were based on the average incidence during 1990 to 1995. For each reported case of hepatitis A we assumed there were 3.28 unreported cases. 32 All reported cases were assumed to be icteric (symptomatic with jaundice). The number of additional anicteric cases was estimated by applying age-specific ratios. 32 We assumed a 1.40% per year ongoing decline for the logarithm of hepatitis A virus infection rates during the period covered by our analysis. 32 For rotavirus disease, we assumed that the cumulative incidence of rotavirus gastroenteritis is 75% in the first 5 years of life, [33] [34] [35] [36] the cumulative incidence of hospitalization visits attributable to rotavirus gastroenteritis in the first 5 years is 1.70%, the cumulative incidence of outpatient visits is 11.14%, the cumulative incidence of emergency department visits is 5.36%, and the cumulative incidence of deaths is 0.00078%. 36 
Estimating the Burden of Diseases With Vaccination
For all diseases except varicella, hepatitis B, pneumococcal diseases, hepatitis A, and rotavirus, we used surveillance data for 2005 to 2009 from the National Notifiable Diseases Surveillance System to estimate the burden of diseases with vaccination in 2009. For varicella, we used the average incidence in 2009 from 4 states (Colorado, Connecticut, Michigan, and Texas) to estimate the total varicella cases in the United States. Based on data from the Varicella Active Surveillance Project, we assumed that 59.5% of reported cases involved persons who had previously received VAR and that these were thus much milder than cases among unvaccinated persons. 37 For hepatitis B, because chronic cases were not reported to the National Notifiable Diseases Surveillance System, we used an established hepatitis B decision analysis model 38 and the vaccine efficacy estimates 39 to estimate the likelihood of hepatitis B infection and sequelae among vaccinated and unvaccinated children in the cohort. For pneumococcal disease, vaccination-era IPD rates and case-fatality rates for IPD were based on data for 2008 to 2009 from the ABCs program. All-cause pneumonia incidence and acute otitis media rates were obtained from the literature. [28] [29] [30] [31] For both hepatitis A and rotavirus diseases, we developed hepatitis A and rotavirus decision analysis models, using the efficacies of the vaccines [40] [41] [42] [43] [44] [45] [46] to estimate the likelihood of hepatitis A and rotavirus infections and their sequelae among vaccinated children in the cohort.
COSTS ASSOCIATED WITH DISEASE Direct Costs
Direct costs for outpatient and inpatient visits and outbreak control, which was not included in the previous analysis, were covered in the analysis. The cost of outpatient visits, average duration of hospital stay, hospitalization costs, and costs for outbreak control for each condition related to these diseases, including congenital rubella syndrome (Table 2) were obtained from HCUPnet, 47 the Marketscan database, 48 and published and unpublished studies. [13] [14] [15] [16] [29] [30] [31] 35, 36, 38, [49] [50] [51] [52] [53] [54] [55] 
Indirect Costs
To estimate the productivity losses from premature mortality, we used the human capital approach. 56 Costs for work loss were determined by the number of days of missed work (for provision of care for sick children, for illness among cohort members, or for resulting disability) multiplied by the daily wage rate associated with the value of lost wage-earning work and the imputed value of housekeeping and home-care activities. We assumed the days of morbidity were distributed randomly throughout the week. NIS data indicate that .80% of children obtained their vaccines from private providers. 58 The cost for administering a vaccine dose during a visit to a private clinic was estimated at $25.68. 15, 16 For the public clinic, we used an administration cost of $7.20. 15, 16 We assumed that caregivers take 2 hours' time off from work to take the child for vaccination (as per previous economic studies 15, 16 ). We assumed that the average cost for these caregivers was $16.75 per hour, and cost for caregiver' s travel to the clinic was $21.60. 36 The severe and mild adverse reaction rates of DTaP, Hib, MMR, and VAR from the previous analyses were used. 7 We assumed that there were no serious side effects for IPV. 59 For HepB, we assumed that 1.1 per 1 000 000 vaccinated children will have anaphylaxis. 60, 61 For PCV7, we assumed that 5 per 1 000 000 vaccinated children will have severe seizure. 62 For HepA, we assumed that 0.17 per 1 000 000 vaccinated children will have severe adverse reactions. 63 For Rota, we assumed that 2250 per 1 000 000 64 of vaccinated infants will have physician visits for adverse events and 10 per 1 000 000 of vaccinated infants will have intussusceptions caused by the first dose (based on data from international setting and no documented risk in the United States), and that the case-fatality rate for intussusception is 0.4%.
Sensitivity Analyses
Sensitivity analyses were used to assess the robustness of our economic estimates and to estimate the impact of potential changes to the immunization program. Univariate sensitivity analyses were performed to assess the effect of varying: (1) pre-vaccine-era disease incidence rates; (2) vaccine-era disease incidence rates; (3) rates of vaccine adverse events; (4) direct costs; (5) the proportion of vaccines purchased in the public versus private sector; (6) vaccine administration cost; (7) the vaccine wastage rate; (8) vaccination coverage; (9) the inclusion of federal, state, and local immunization program management expenditures and excise tax; and (10) costs associated with parent time lost from work and travel. Each parameter was assessed individually into the sensitivity analyses. We also performed the worst-case scenario analysis: the combination of the worst case of items 1 to 9. Table 4 shows both the direct and societal BCRs from sensitivity analyses when the value of each parameter was varied in a plausible range. The incidences of some diseases likely have decreased over time even without vaccination. In a conservative scenario, reducing pre-vaccine incidence rates by 10%, the resulting direct and societal BCRs were 2.6 and 9.0, respectively. Disease incidence in the vaccination era may have been underestimated. To test the effect, we modeled vaccination era diphtheria, tetanus, pertussis, measles, mumps, and rubella rates that were 1000% of the rates in the base case analysis; the direct and societal BCRs did not change substantially. When we doubled the vaccine adverse event rates used in the base case analysis, the direct and societal BCRs also did not change substantially. With a lower or higher wastage rate, the BCRs changed only slightly. When The sensitivity analyses highlight several key aspects of the current routine immunization program. First, the early childhood vaccines are very effective and have reduced levels of vaccinepreventable disease to remarkably low levels. Current levels of most vaccine-preventable diseases are so low that modeling a 10-fold increase in reported incidence rates does not alter the BCR substantially. Similarly, these vaccines are safe, and even when modeling adverse events rates far higher than those currently reported, the BCR of the program remains positive. As shown in Table 4 , the current model was most sensitive to increases in administration costs. Data on the probability distributions of variables are unavailable, which prevents us from conducting a Monte Carlo simulation for a multivariate probabilistic sensitivity analysis and estimating confidence intervals. Even with the worst-case scenario, the BCRs were still .1.
RESULTS
Base Case
Sensitivity Analyses
Routine childhood immunization coverage in the United States has improved in recent years. 66 Although overall coverage is currently high, several factors could potentially affect this success, including vaccine hesitancy, 67 concern by private physicians over insufficient reimbursement for routine childhood immunizations, 68 failure of some insurance plans to cover all recommended vaccines, 69 and the possibility that underinsured children are less likely to be fully immunized than fully privately insured children. 70 Some of these factors highlight economic challenges for ensuring that all US children are protected from vaccine-preventable diseases. 71 Recent health care reform legislation addresses most, but not all, of the challenges to achieving and maintaining optimal vaccination rates among US children, and may present some important opportunities to assess the impact of improved financing support. 72 For example, private insurers will be required to cover the cost of vaccination recommended by the Advisory Committee on Immunization Practices without costsharing. Monitoring the impact of these changes on coverage rates will provide useful information for future vaccine financing policy decisions. Data on benefits and costs of the current program will be increasingly important as decisions on immunization program financing are made.
Our evaluation has a number of limitations. We might have underestimated the full impact of the newest vaccines to be introduced (HepA and Rota coverage
has not yet reached that of other vaccines). We also underestimated the full impact of PCV7 on pneumococcal disease from herd immunity, which has resulted in significantly reduced disease among children and adults not directly vaccinated with PCV7; 73 this would result in underestimation of the NPV and the BCRs. New 13-valent pneumococcal conjugate vaccine, which replaced PCV7 vaccine, has been licensed and recommended for children in the United States since February 2010. 74 Thirteen-valent pneumococcal conjugate vaccine is more expensive than PCV7. However, it adds 6 additional serotypes, thereby providing more protection against the most common strains of pneumococcal bacteria responsible for severe pneumococcal infections among children. We also did not include the costs associated with pain and suffering from diseases or the value of potential benefits of the immunization program to children other than immunization itself that accrue from visiting a health care provider to obtain vaccines.
Vaccines are developed and used to prevent disease and its attendant consequences, including pain, suffering, long-term disabilities, and death. The increased number of vaccines incorporated into the early childhood schedule has raised questions about the value of the vaccination series. Our analysis demonstrates the substantial health benefits associated with vaccinating young children, as well as an impressive return on the investment of vaccines and immunization services. In this context, our data confirm that the vaccines currently recommended for young children represent not only a major public health victory in terms of disease prevention, but also an excellent public health "buy" in terms of dollars and cents.
